Download PDF
Thromb Haemost 2005; 93(01): 80-87
DOI: 10.1160/TH04-04-0230
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Heterogeneity of anti-β2-glycoprotein I antibodies

A factor of variability in test results
Marielle Sanmarco
1   Fédération Autoimmunité et Thrombose, Laboratoire d’Immunologie, Hôpital de La Conception, Marseille, France
,
Nathalie Bardin
1   Fédération Autoimmunité et Thrombose, Laboratoire d’Immunologie, Hôpital de La Conception, Marseille, France
,
Miri Blank
2   Department of Medicine 'B' and Research Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel
,
Veronique Pascal
1   Fédération Autoimmunité et Thrombose, Laboratoire d’Immunologie, Hôpital de La Conception, Marseille, France
,
Marie Christine Alessi
3   Laboratoire d’Hématologie, Hôpital de La Timone, Marseille, France
,
Françoise Dignat-George
4   INSERM U 608, Laboratoire d’Hématologie et d’Immunologie, UFR de Pharmacie, Marseille, France
,
Yehuda Shoenfeld
2   Department of Medicine 'B' and Research Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel
,
Jean Robert Harlé
5   Service de Médecine Interne, Hôpital de La Conception, Marseille, France
› Author Affiliations
Further Information

Publication History

Received 14 April 2004

Accepted after revision 14 September 2004

Publication Date:
14 December 2017 (online)

   Permissions and Reprints

Summary

The aim of this study was to evaluate the heterogeneity of IgG-anti- β2 -glycoprotein I antibodies (IgG-aβ2 GPI) as regarding their reactivity pattern against different sources of human β2 GPI,their avidity and their association with clinical events of antiphospholipid syndrome (APS).Three thousand six hundred and eightyfour consecutive patient sera were routinely tested for IgG-a β2 GPI over 1 year using an in-house ELISA with 2 different commercial preparations of human purified β2GPI. Of the 340 sera found positive, all those clinically documented were included in this study; 61 were positive with only one preparation (S1) and 59 with both (S2).The results of ELISA were confirmed by Western blot. Heterogeneity was stressed by testing sera with a human recombinant protein and 3 β2 GPI-related peptides. No contribution of glycosylation in the binding to β2GPI was found.The avidity indices for each protein were significantly higher in S1 than in S2 (p = 0.0021). S2 were more associated with antiphospholipid antibodies than S1 (75% versus 21% ; p <0.0001).A similar frequency of the main clinical features of APS was found in S1 and S2 sera (69% and 71%, respectively). In conclusion, our data show a heterogeneity in the antigenic reactivity pattern of IgG- a β2 GPI and a relationship between a binding profile and antibody avidity.This heterogeneity could represent a crucial factor of variability in test results and underlines the difficulty of getting standardisation.

Keywords

β2-glycoprotein I - heterogeneity - avidity - antiphospholipid syndrome
 

  • References

  • 1 Najmey SS, Keil LB, Adib DY. et al The association of antibodies to beta 2 glycoprotein I with the antiphospholipid syndrome: a meta-analysis. Ann Clin Lab Sci 1997; 27: 41-6.
    PubMedGoogle Scholar
  • 2 Wilson WA, Gharavi AE, Koike T. et al International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
    CrossrefPubMedGoogle Scholar
  • 3 Asherson RA, Khamashta MA, Ordi-Ros J. et al The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore). 1989; 68: 366-74.
    CrossrefPubMedGoogle Scholar
  • 4 Alarcon-Segovia D, Deleze M, Oria CV. et al Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore). 1989; 68: 353-65.
    CrossrefPubMedGoogle Scholar
  • 5 Reber G, Schousboe I, Tincani A. et al Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002; 88: 66-73.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci USA 1984; 81: 3640-4.
    CrossrefPubMedGoogle Scholar
  • 7 Bouma B, de Groot PG, van den Elsen JM. et al Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166-74.
    CrossrefPubMedGoogle Scholar
  • 8 Schwarzenbacher R, Zeth K, Diederichs K. et al Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999; 18: 6228-39.
    CrossrefPubMedGoogle Scholar
  • 9 Hunt JE, Simpson RJ, Krilis SA. Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 1993; 90: 2141-5.
    CrossrefPubMedGoogle Scholar
  • 10 Roubey RA, Eisenberg RA, Harper MF. et al "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995; 154: 954-60.
    PubMedGoogle Scholar
  • 11 Tincani A, Spatola L, Prati E. et al The antibeta2- glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species’ evolution. J Immunol 1996; 157: 5732-8.
    PubMedGoogle Scholar
  • 12 Matsuura E, Igarashi Y, Yasuda T. et al Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-62.
    CrossrefPubMedGoogle Scholar
  • 13 Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci USA 1998; 95: 15542-6.
    CrossrefPubMedGoogle Scholar
  • 14 McNeeley PA, Dlott JS, Furie RA. et al Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Haemost 2001; 86: 590-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Igarashi M, Matsuura E, Igarashi Y. et al Human beta2-glycoprotein I as an anticardio-lipin cofactor determined using mutants expressed by a baculovirus system. Blood 1996; 87: 3262-70.
    PubMedGoogle Scholar
  • 16 Koike T, Ichikawa K, Atsumi T. et al Beta 2-glycoprotein I-anti-beta 2-glycoprotein I interaction. J Autoimmun 2000; 15: 97-100.
    CrossrefPubMedGoogle Scholar
  • 17 Blank M, Shoenfeld Y, Cabilly S. et al Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 1999; 96: 5164-8.
    CrossrefPubMedGoogle Scholar
  • 18 Verrot D, SanMarco M, Dravet C. et al Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997; 103: 33-7.
    CrossrefPubMedGoogle Scholar
  • 19 Vlachoyiannopoulos PG, Petrovas C, Tektonidou M. et al Antibodies to B2-GPI: Urea resistance, binding , specificity and association with thrombosis. J Clin Immunol 1998; 18: 380-91.
    CrossrefPubMedGoogle Scholar
  • 20 Cabral AR, Amigo MC, Cabiedes J. et al The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am J Med 1996; 101: 472-81.
    CrossrefPubMedGoogle Scholar
  • 21 Shoenfeld Y, Krause I, Kvapil F. et al Prevalence and clinical correlations of antibodies against six β 2-glycoprotein I-related peptides in the antiphospholipid syndrome. J Clin Immunol 2003; 23: 375-81.
    PubMedGoogle Scholar
  • 22 Schousboe I. Characterization of subfractions of beta 2-glycoprotein I: evidence for sialic acid microheterogeneity. Int J Biochem 1983; 15: 35-44.
    CrossrefPubMedGoogle Scholar
  • 23 Gries A, Nimpf J, Wurm H. et al Characterization of isoelectric subspecies of asialo-beta 2-glycoprotein I. Biochem J 1989; 260: 531-4.
    CrossrefPubMedGoogle Scholar
  • 24 Brighton TA, Dai YP, Hogg PJ. et al Microheterogeneity of beta-2 glycoprotein I: implications for binding to anionic phospholipids. Biochem J 1999; 340: 59-67.
    CrossrefPubMedGoogle Scholar
  • 25 Arvieux J, Roussel B, Ponard D. et al IgG2 subclass restriction of anti-b2 glycoprotein 1 antibodies in autoimmune patients. Clin Exp Immunol 1994; 95: 310-5.
    PubMedGoogle Scholar
  • 26 Zanon E, Prandoni P, Vianello F. et al Antibeta2- glycoprotein I antibodies in patients with acute venous thromboembolism: prevalence and association with recurrent thromboembolism. Thromb Res 1999; 96: 269-74.
    CrossrefPubMedGoogle Scholar
  • 27 Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899-906.
    PubMedGoogle Scholar
  • 28 Bruce IN, Clark-Soloninka CA, Spitzer KA. et al Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria : a single center study and literature review. J Rheumatol 2000; 27: 2833-7.
    PubMedGoogle Scholar
  • 29 Day HM, Thiagarajan P, Ahn C. et al Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J Rheumatol 1998; 25: 667-74.
    PubMedGoogle Scholar
  • 30 Forastiero RR, Martinuzzo ME, Carreras LO. Binding properties of antibodies to prothrombin and beta2-glycoprotein I (beta2-GPI) assayed by ELISA and dot blot. Clin Exp Immunol 1999; 118: 480-6.
    CrossrefPubMedGoogle Scholar
  • 31 Previtali S, Barbui T, Galli M. Anti-beta2-glycoprotein I and anti-prothrombin antibodies in antiphospholipid- negative patients with thrombosis: a case control study. Thromb Haemost 2002; 88: 729-32.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Galli M, Luciani D, Bertolini G. et al Antibeta2- glycoprotein I, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-23.
    CrossrefPubMedGoogle Scholar
  • 33 Lynch A, Byers T, Emlen W. et al Association of antibodies to beta2-Glycoprotein 1 with pregnancy loss and pregnancy-induced hypertension : a prospective study in low-risk pregnancy. Obstet Gynecol 1999; 93: 193-8.
    PubMedGoogle Scholar
  • 34 Franklin RD, Hollier N, Kutteh WH. Beta2-Glycoprotein 1 as a marker of antiphospholipid syndrome in women with recurrent pregnancy loss. Fertil Steril 2000; 73: 531-5.
    CrossrefPubMedGoogle Scholar
  • 35 Gris JC, Quere I, Sanmarco M. et al Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstetricians and Haematologists Study-NOHA. Thromb Haemost 2000; 84: 228-36.
    Article in Thieme ConnectPubMedGoogle Scholar